As Consolidation Gathers Steam, Big Pharma Ramps Up India Staffing For The Long Haul
This article was originally published in The Pink Sheet Daily
Executive Summary
Industry giants including Merck and GSK are bullish on growth prospects in India.
You may also be interested in...
As Pfizer-Wyeth Combine Eye Vaccines Business, Novartis, GSK, Sanofi-Aventis And Indian Companies Brace For The Challenge
MUMBAI - These may be early days for Pfizer and Wyeth to analyze growth strategies of their vaccines business in emerging markets like India, but existing players like GlaxoSmithKline, Merck, Novartis and a host of home-grown companies like Panacea Biotec, Serum Institute and Shantha Biotech already seem well positioned to accelerate their growth in the quickly emerging vaccines market
Novartis Designs “Arogya Parivar” To Reach Real India In Its Rural Centers
MUMBAI - Swiss drug maker Novartis recently launched its ace anti-diabetes drug Galvus in India to take Merck's Januvia head on, but the company's larger focus seems to be shifting fast from the mega cities to the rural market where "real India lives.
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.